
via The Wistar Institute
Researchers at The Wistar Institute and the University of South Florida have advanced a novel compound that specifically targets the endoplasmic reticulum (ER) stress response that is frequently hyperactivated in cancer and promotes survival of cancer cells during stressful conditions. The new compound has unique chemical properties that allow for precise activation and can be used for tracking its activity in vivo thanks to the emission of fluorescence.
Research was published online in the Journal of Medicinal Chemistry.
The ER is a cellular structure that oversees protein folding and assembly, and it activates stress response mechanisms in response to the accumulation of misfolded proteins or other stressful conditions, including low oxygen.
“Certain cancers rely on the protective role of the ER stress response to sustain their growth in stressful environmental conditions,” said Chih-Chi Andrew Hu, Ph.D., associate professor in Wistar’s Immunology, Microenvironment & Metastasis Program, and co-lead author on the study with Juan R. Del Valle, Ph.D., from the University of South Florida. “We and other groups showed that genetically and pharmacologically targeting the ER is a very effective way to attack various tumors.”
The Hu lab has been actively advancing a research program for development of compounds to block vital functions of the ER stress response, specifically inhibitors of the IRE1 protein that senses the ER stress and responds by activating a cascade of cellular events. In addition to inducing tumor cell apoptosis, these compounds activate antitumor T-cell function and inhibit tumor-associated immunosuppressive cells in vivo in mouse models, resulting in tumor shrinkage.
“This class of inhibitors has shown therapeutic promise in several cancer types, including chronic lymphocytic leukemia and Burkitt lymphoma,” said Hu. “Therefore, we are very interested in advancing them to the clinic.”
In this study, through a series of chemical modifications, Hu and collaborators created a molecule called PC-D-F07 that is pharmacologically inactive and requires UV irradiation to be “turned on” and converted into the active D-F07, which is a very potent inhibitor of IRE-1 function.
The novel prodrug strategy enhances the efficacy of IRE-1 inhibitors and allows fine control of their activity at a precise time and location by UV irradiation. Importantly, once active, D-F07 emits fluorescence that can be tracked in cells and potentially in vivo, providing a real-time therapy readout. This new strategy for stimulus-mediated release of pharmacological activity provides a promising platform to target the ER stress response for anticancer therapy and for developing other potent inhibitors.
Learn more: Enhanced Anticancer Compound May Allow for Precise Activation and Tracking of Treatment
The Latest on: Cancer treatment
via Google News
The Latest on: Cancer treatment
- The Challenge 's Ashley Cain Says He Found Out Daughter's Cancer Returned the Day She Left Hospitalon February 23, 2021 at 7:59 pm
Ashley Cain/instagram Ashley Cain and daughter Azaylia Diamond. The Challenge's Ashley Cain has a heartbreaking update into his baby daughter Azaylia Diamond's condition four mont ...
- New Treatment to Prevent and Treat Endometrial Cancer Recurrenceon February 23, 2021 at 6:42 pm
Endocrine-targeted therapies and an assessment of biomarkers in hormone and insulin signaling pathways were found to be useful in endometrial cancer prevention.
- Alternative splicing and cancer: a systematic reviewon February 23, 2021 at 5:27 pm
The abnormal regulation of alternative splicing is usually accompanied by the occurrence and development of tumors, which would produce multiple different isoforms and diversify protein expression.
- Androgen Cycling Shows Promise in Castration-Resistant Prostate Canceron February 23, 2021 at 4:01 pm
A treatment strategy based on manipulation of testosterone levels showed promise as a potential aid for managing castration-resistant prostate cancer (CRPC), according to a randomized ...
- Prostate Cancer Treatment Heightens Arrhythmia Riskon February 23, 2021 at 1:20 pm
More serious ECG changes such as torsade de pointes and ventricular fibrillation are rare, but monitoring is advised.
- Rakhi Sawant shares heartwrenching pics of mother; asks for prayers as she undergoes cancer treatmenton February 23, 2021 at 11:37 am
Rakhi Sawant's mother Jaya has a huge tumour in her gallbladder, which is cancerous and can't be operated upon. Doctors were going to start the chemotherapy.
- Biomarkers dramatically improve success rates of new cancer drugson February 23, 2021 at 10:14 am
In recent decades there have been some big advances in developing new cancer medicines, such as Herceptin, the targeted drug to treat women diagnosed with HER2-positive breast cancer. Despite these ...
- Study shows new treatment pathway to prevent and treat endometrial cancer recurrenceon February 23, 2021 at 10:14 am
In a new study led by Yale Cancer Center, researchers demonstrate sex hormones and insulin growth factors are associated with recurrence risk of endometrial cancer. The findings suggest ...
- Oral Cancer Treatment Market : Key Facts and Forecast Predictions Presentedon February 23, 2021 at 6:06 am
"The report on the global oral cancer treatment market provides qualitative and quantitative analysis for the period from 2017 to 2025. The report predicts the global oral cancer treatment market to ...
- Discovery of cancer cell vulnerability identifies potential treatment targeton February 23, 2021 at 4:43 am
International data-sharing fast-tracks promising discoveries in the fight against cancer Image of a triple negative breast cancer cell undergoing abnormal division after inhibition of KIF18A. (Credit: ...
via Bing News